We are live on ! Find out more
AGMB

AgomAb Therapeutics NV
AGMB

32 hedge funds and large institutions have $245M invested in AgomAb Therapeutics NV in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

47.92% more ownership

Funds ownership: 0% → 47.92% (+48%)

Holders
32
Holders Change
+32
Holders Change %
–
% of All Funds
0.39%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.04%
New
32
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EFM
EQT Fund Management
Luxembourg
+$72.8M
2
S
Sanofi
France
+$39.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$34.9M
4
TCM
TCG Crossover Management
California
+$29.1M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$22.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
$248K +$336K +23,726 New
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$161K +$217K +15,326 New
Two Sigma Investments
28
Two Sigma Investments
New York
$149K +$202K +14,241 New
Jane Street
29
Jane Street
New York
$134K +$181K +12,794 New
UBS Group
30
UBS Group
Switzerland
$67.5K +$91.2K +6,437 New
Morgan Stanley
31
Morgan Stanley
New York
$31.7K +$42.8K +3,025 New
SS
32
SBI Securities
Japan
$21 +$28 +2 New
1
2

AGMB Hedge Fund Activity: Q1 2026 in Review

32 of the 8,169 institutional investors tracked by Wall St. Rank reported a position in AgomAb Therapeutics NV (AGMB) for Q1 2026, worth a combined $245M.

Buyers outnumbered sellers: 32 funds opened new AGMB positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was EQT Fund Management, opening a new position worth an estimated $72.8M.

  • 32 institutional investors held AgomAb Therapeutics NV (AGMB) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $245M of AgomAb Therapeutics NV stock for Q1 2026.
  • 32 funds opened new AgomAb Therapeutics NV positions in Q1 2026 and 0 closed out, a net change of +32 holders.
  • The largest AgomAb Therapeutics NV buyer in Q1 2026 was EQT Fund Management, an estimated $72.8M added.

Based on aggregated 13F filings for Q1 2026.